Cancer, by definition, refers to uncontrolled cellular growth and is often a by-product of corrupted cellular processes, such as those mediated by cell surface signalling receptors. Of particular interest to our group is the cell surface receptor ErbB2, which plays an important role in breast cancer. The focus of our research is to develop novel anti-cancer therapies that target these receptors and "rewire" the associated signalling events. By rewiring the signalling events, cells can be targeted for death rather than the uncontrolled growth associated with cancer. We have previously shown the feasibility of our approach through rewiring the signalling pathway of ErbB2 using genetic techniques. Our current focus however is to engineer small drug-like molecules capable of the same cell signal rewiring. The ultimate goal is that these molecules will be developed as anti-cancer therapeutics that can enter the cell and convert ErbB2 signalling to cell death.